EPS for Esperion Therapeutics, Inc. (ESPR) Expected At $-1.60

October 13, 2018 - By Darrin Black

Investors sentiment decreased to 0.95 in 2018 Q2. Its down 0.55, from 1.5 in 2018Q1. It worsened, as 43 investors sold Esperion Therapeutics, Inc. shares while 35 reduced holdings. 18 funds opened positions while 56 raised stakes. 26.84 million shares or 9.29% more from 24.56 million shares in 2018Q1 were reported.
Geode Cap Mgmt Ltd Liability has 214,625 shares. C Worldwide Group Holdings A S holds 0% or 4,304 shares in its portfolio. Proshare Advsr Ltd Liability Corp accumulated 14,271 shares. Sectoral Asset Inc owns 0.92% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 210,468 shares. Meditor Gru Incorporated Ltd invested 20.13% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Royal Savings Bank Of Canada has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 13,235 shares. Tower Rech Cap Limited Com (Trc) holds 0% or 962 shares. Blackrock Inc owns 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 1.81 million shares. Weiss Asset L P invested in 5,427 shares or 0.02% of the stock. Pnc Ser Group Inc holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 6 shares. Point72 Asset Mngmt L P holds 364,100 shares. 133,800 were reported by Gam Ag. Natixis has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Rudman Errol M has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Citigroup Inc stated it has 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report $-1.60 EPS on November, 6.They anticipate $0.26 EPS change or 13.98 % from last quarter’s $-1.86 EPS. After having $-1.71 EPS previously, Esperion Therapeutics, Inc.’s analysts see -6.43 % EPS growth. The stock increased 0.22% or $0.1 during the last trading session, reaching $46.22. About 356,303 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 8.71% since October 14, 2017 and is downtrending. It has underperformed by 24.33% the S&P500.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 8 analysts covering Esperion (NASDAQ:ESPR), 4 have Buy rating, 3 Sell and 1 Hold. Therefore 50% are positive. Esperion had 9 analyst reports since April 19, 2018 according to SRatingsIntel. Credit Suisse maintained the shares of ESPR in report on Friday, May 4 with “Outperform” rating. The rating was downgraded by JP Morgan to “Underweight” on Thursday, May 3. The stock has “Underperform” rating by Bank of America on Wednesday, May 2. The rating was upgraded by Citigroup to “Buy” on Friday, August 17. Deutsche Bank maintained it with “Buy” rating and $7500 target in Thursday, May 3 report. As per Wednesday, July 11, the company rating was downgraded by Northland Capital. JMP Securities maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, May 2. JMP Securities has “Buy” rating and $15300 target. Northland Capital maintained the stock with “Buy” rating in Thursday, April 19 report. J.P. Morgan downgraded the stock to “Sell” rating in Thursday, May 3 report.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.24 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Another recent and important Esperion Therapeutics, Inc. (NASDAQ:ESPR) news was published by Seekingalpha.com which published an article titled: “Esperion Therapeutics: Hold For PDUFA Date” on September 25, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.